<SEC-DOCUMENT>0001558370-21-016986.txt : 20211222
<SEC-HEADER>0001558370-21-016986.hdr.sgml : 20211222
<ACCEPTANCE-DATETIME>20211222065527
ACCESSION NUMBER:		0001558370-21-016986
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20211222
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211222
DATE AS OF CHANGE:		20211222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		211510990

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>plx-20211222x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8003.26990 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 12/22/2021 11:52:13 AM -->
      <!-- iXBRL Library version: 1.0.8003.27000 -->
      <!-- iXBRL Service Job ID: e65be3cb-03cc-4fd3-b2c1-7db962a7e57c -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:plx="http://protalix.com/20211222" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" name="dei:EntityCentralIndexKey" id="Tc_BTTMuXwL2EyPjlGhGXAyjw_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" name="dei:AmendmentFlag" id="Tc_QAZNlvVmmEadpHL4eE11tw_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="plx-20211222.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-22</xbrli:startDate><xbrli:endDate>2021-12-22</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_0e9ca0c2_ebd9_4bd2_825b_93ebacf24761"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" name="dei:DocumentType" id="Narr_GZpDRhuzZEerNWgWRPCJaQ"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of Earliest Event Reported): </b><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_431cSt0_50mYBGraa2QtfA"><b style="font-weight:bold;">December&#160;22, 2021</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" name="dei:EntityRegistrantName" id="Narr_BiFl7KTQ6EOGzM8AMf22Eg"><b style="font-weight:bold;">Protalix BioTherapeutics,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_db44e2d3_a4d8_4690_a9da_b28605fc200d"></a><a id="Tc_2tt1DxPAIkiCYRwjbCiYOA_2_0"></a><a id="Tc_TQCMqBwkoUSv3Cr3E1NCuA_2_2"></a><a id="Tc_RWOuCkkvG0u47MOJMWxTug_2_4"></a><a id="Tc_kCxeVKiLVUOE91scN647dQ_6_0"></a><a id="Tc_pANzlWssK0yAfiQklkoqpA_7_0"></a><a id="Tc_AtZjIfsTwkaDaKJUsLSeZg_7_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_zrqhGfjebEm6K3ytZxi6_w_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" name="dei:EntityFileNumber" id="Tc_-C-Cj_S2WUSm7V2s3iKgsg_1_2"><b style="font-weight:bold;">001-33357</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" name="dei:EntityTaxIdentificationNumber" id="Tc_Exh1MAeuJkWlK6pDTLIB_Q_1_4"><b style="font-weight:bold;">65-0643773</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><br /><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission File Number)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" name="dei:EntityAddressAddressLine1" id="Tc_r1KFQWCodku_LkyNbqIwFg_4_0"><b style="font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" name="dei:EntityAddressAddressLine2" id="Tc_rh5osS5bAkWfrulYV5HNxw_5_0"><b style="font-weight:bold;">Suite 100</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" name="dei:EntityAddressCityOrTown" id="Narr_2B-vNzHF2kaVAejO-RFQcQ"><b style="font-weight:bold;">Hackensack</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" name="dei:EntityAddressStateOrProvince" id="Narr_ppcSCaOqPkOybELWhh1kyA"><b style="font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" name="dei:EntityAddressPostalZipCode" id="Tc_DH5KRDoORU6U3MhkvarZ4w_6_4"><b style="font-weight:bold;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">&#160;<b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code </b><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" name="dei:CityAreaCode" id="Narr_ujUSOvm8xE-mSa6NUikTRQ"><b style="font-weight:bold;">201</b></ix:nonNumeric><b style="font-weight:bold;">-</b><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" name="dei:LocalPhoneNumber" id="Narr_c3IMqfLuMk66O8rpKMvnaQ"><b style="font-weight:bold;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name or former address, if changed since last report.)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:10pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_VN0IoKP4EkqAWxBYgdmLpg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_1BbteBbaBUijuInXVd3MtQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_6Jw7rhA2MEq0LeETLukPgQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_ayfTsc6JwE2flfm-DPpcAw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e77e804a_d223_4729_927d_c6bf13fbe4e3"></a><a id="Tc_rcv8mkSx10en7cAJNKubtw_1_0"></a><a id="Tc_1vS9Q05TTEWl_qHT_UgNTA_1_1"></a><a id="Tc_dZr1Sz5ROEaXCIPJO7HsNQ_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" name="dei:Security12bTitle" id="Tc_H2dHTd2ZnUev3gEVDJe3xA_2_0">Common stock, $0.001 par value</ix:nonNumeric></p></td><td style="vertical-align:top;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" name="dei:TradingSymbol" id="Tc_MtF2o-AgVEqlJqdji3nqNQ_2_1">PLX</ix:nonNumeric></p></td><td style="vertical-align:top;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc__mS0qDKbdU-6-M-gUoiBDw_2_2">NYSE American</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_txuug4Xl3U2q7UAr_j98ZA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:Times New Roman;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;7.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Regulation FD Disclosure</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On December&#160;22, 2021, Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) issued a press release containing a copy of a letter to its stockholders discussing recent corporate developments. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (&#8220;Current Report&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits</b></p><a id="a02"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:86.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit No.</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Description</p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20211222xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release dated December&#160;22, 2021</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: December&#160;22, 2021</p></td><td colspan="3" style="vertical-align:top;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:40.02%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>plx-20211222xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 12/22/2021 11:52:30 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:51.85%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Exhibit 99.1</b></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.88%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><img src="plx-20211222xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:39pt;width:128.25pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Protalix BioTherapeutics Issues 2021 Letter to Stockholders</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CARMIEL, Israel</b><font style="font-family:'Times New Roman','Times','serif';">, December&#160;22, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Times New Roman','Times','serif';"> plant cell-based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders and the investment community.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Dear Protalix Stockholders,</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">As we look back and reflect on this past year, I am proud of our team and of the progress we have made in a time of continued Covid-19-related uncertainty across all corners of the globe. While the pandemic has added, and continues to add, many challenges that are out of our control, we remain resolute and focused on that which was within our control, including our operational, clinical and regulatory work. We continue to make progress on all fronts and firmly believe that we are on the right path forward towards meaningful, value-adding milestones and transformational catalysts.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">I am pleased to briefly highlight some of our more notable milestones achieved in 2021.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Regulatory Advancements</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Together with our development and commercialization partner, Chiesi Farmaceutici S.p.A., we completed a Type A meeting in October with the U.S.&#160;Food and Drug Administration (FDA) for the biologics license application (BLA) for PRX-102 for the treatment of adult patients with Fabry disease. We gained clarity regarding the FDA&#8217;s expectations and confirmed our pathway for resubmission of a PRX-102 BLA, planned for the second half of 2022.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">In addition, we have made important progress in our pre-submission activities toward an anticipated Marketing Authorization Application (MAA) with the European Medicines Agency (EMA). In our October meeting with the Rapporteur and Co-Rapporteur of the EMA, we and Chiesi discussed the MAA scope and gained general support for the anticipated PRX-102 MAA submission planned for the first quarter of 2022.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Clinical Advancements</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The last patient in our Phase III </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">BALANCE</i><font style="font-family:'Times New Roman','Times','serif';"> clinical trial, a 24-month, randomized, double blind, active control study of PRX-102 in Fabry patients with impaired renal function, received the final dose in October 2021. We anticipate releasing un-blinded final data in the second quarter of 2022 after all remaining patients have completed the 24-month treatment period. The determination to plan the PRX-102 MAA submission for the first quarter of 2022 was based on the interim analysis of the 12-month data generated from the </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">BALANCE</i><font style="font-family:'Times New Roman','Times','serif';"> study, which were released in June 2021, in combination with previously reported positive data from our Phase&#160;III </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">BRIGHT</i><font style="font-family:'Times New Roman','Times','serif';"> and </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">BRIDGE</i><font style="font-family:'Times New Roman','Times','serif';"> clinical trials.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Earlier in the year, we announced positive topline results from our Phase&#160;III </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">BRIGHT</i><font style="font-family:'Times New Roman','Times','serif';"> clinical trial, a 12-month, open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of PRX-102 via intravenous (IV) infusions of 2&#160;mg/kg administered every 4 weeks in Fabry patients previously treated with a commercially available enzyme replacement therapy (ERT). Topline results of the </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">BRIGHT</i><font style="font-family:'Times New Roman','Times','serif';"> study indicate that 2&#160;mg/kg of PRX-102 administered by IV infusion every 4 weeks are well tolerated among treated patients, and stable clinical presentation was maintained in adult Fabry patients.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Corporate &amp; Financial Developments</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Earlier this fall, we strengthened our balance sheet through exchanges of a substantial majority of our outstanding 7.50% Senior Secured Convertible Notes due 2021 for a combination of cash and new notes. In brief, we issued new 7.50% Senior Secured Convertible Notes due 2024 with an aggregate of $54.65&#160;million principal amount and made principal and interest payments of approximately $27.00&#160;million. The remaining 2021 Notes were repaid on the November 2021 maturity date. Over the course of the year, we raised almost $50.00&#160;million in new equity, and we have an At-the-Market offering program in place should we find market conditions favorable for additional financing. These transactions secured our balance sheet, and we are gratified to be in a solid financial position to support our plans and strategies through our important, value-enhancing milestones.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Looking Forward </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We have much to be thankful for this year, including our progress towards our BLA resubmission in the United States; important clarity on an MAA submission in Europe; positive data and progress across all of our clinical trials and a strengthened balance sheet. Going into the new year, we look forward with great anticipation to continuing our progress in advancing a potential good alternative for the Fabry community, and thank our employees for their tireless efforts in driving Protalix forward and building on our scientific foundation. We also take this opportunity to express our appreciation for the close collaboration we have with Chiesi, our commercial partner. Finally, we would like to thank you, our stockholders, for your support and look forward to sharing our successes with you.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Sincerely,</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Dror Bashan, President &amp; Chief Executive Officer</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">About Protalix BioTherapeutics, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S.&#160;Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix&#8217;s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Protalix&#8217;s first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Protalix&#8217;s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human &#945;-Galactosidase-A protein for the treatment of Fabry disease; alidornase alfa or PRX-110, for the treatment of various human respiratory diseases or conditions; PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of refractory gout; PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and &#8220;intend,&#8221; and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings for the clinical trial. Factors that might cause material differences include, among others: risks related to the timing and progress of the preparation of an updated BLA addressing the CRL for PRX-102; risks related to the timing, progress and likelihood of final approval by the FDA of a resubmitted BLA for PRX-102 and, if approved, whether PRX-102 will be commercially successful; the risk that the FDA, the EMA or other foreign regulatory authorities may not accept or approve a marketing application filed for PRX-102 or any of our other product candidates; failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and or lack of sufficient funding to finance our clinical trials; the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will have undesirable side effects or other unexpected characteristics; risks relating to our ability to make required payments under our outstanding convertible notes or any other indebtedness as they come due and our ability to obtain additional financing and raise capital as necessary should the regulatory approval process become more extended; risks associated with </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">the COVID-19 outbreak and variants, which may adversely impact our business, preclinical studies and clinical trials; risks relating to our evaluation and pursuit of strategic alternatives; risks relating to our ability to manage our relationship with our collaborators, distributors or partners; risks relating to changes to interim, topline or preliminary data from clinical trials that we announce or publish; risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital; risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector; our dependence on performance by third-party providers of services and supplies; the impact of development of competing therapies and/or technologies by other companies; risks related to our supply of drug product to Pfizer; risks related to our expectations with respect to the potential commercial value of our product and product candidates; risks relating to the compliance by Funda&#231;&#227;o Oswaldo Cruz, an arm of the Brazilian Ministry of Health, with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement; potential product liability risks, and risks of securing adequate levels of related insurance coverage; the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties; risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere; and the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption of the operations of regulatory authorities, our subsidiaries, our manufacturing facilities and our customers, suppliers, distributors, collaborative partners, licensees and clinical trial sites; and other factors described in our filings with the U.S.&#160;Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Investor Contact</b><font style="font-family:'Times New Roman','Times','serif';"><br></font><font style="font-family:'Times New Roman','Times','serif';">Chuck Padala, Managing Director<br>LifeSci Advisors<br>646-627-8390<br></font><font style="font-family:'Times New Roman','Times','serif';">chuck@lifesciadvisors.com</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Source: Protalix BioTherapeutics, Inc.</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:7.5pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">###</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:avoid;width:75.81%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>plx-20211222xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20211222xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  T *L# 2(  A$! Q$!_\0
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M[XRUEM5E%K;Z@(9;:XDXC8JFQEW= PP#@]C0!LRZU(-:O-*M[,RSV]FMTN9
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=8I%C122JJI;DD#&:** %9%;&Y0<<C(I:** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>plx-20211222.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8003.26990 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/22/2021 11:52:17 AM-->
<!--Modified on: 12/22/2021 11:52:17 AM-->
<xsd:schema targetNamespace="http://protalix.com/20211222" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:plx="http://protalix.com/20211222" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20211222_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20211222_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>plx-20211222_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8003.26990 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/22/2021 11:52:17 AM-->
<!--Modified on: 12/22/2021 11:52:17 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="plx-20211222.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="plx_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>plx-20211222_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8003.26990 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/22/2021 11:52:17 AM-->
<!--Modified on: 12/22/2021 11:52:17 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="plx-20211222.xsd#DocumentDocumentAndEntityInformation" roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="plx-20211222.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637757707379389969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_637757707379389969" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637757707379389969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_637757707379389969" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637757707379389969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_637757707379389969" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637757707379389969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_637757707379389969" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637757707379389969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637757707379389969" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637757707379399971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637757707379399971" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637757707379399971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_637757707379399971" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637757707379399971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2_637757707379399971" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637757707379399971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_637757707379399971" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637757707379399971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_637757707379399971" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637757707379399971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_637757707379399971" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637757707379399971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_637757707379399971" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637757707379399971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_637757707379399971" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637757707379399971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_637757707379399971" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637757707379399971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_637757707379399971" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637757707379409980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_637757707379409980" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637757707379409980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637757707379409980" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637757707379409980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_637757707379409980" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637757707379409980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_637757707379409980" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637757707379409980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_637757707379409980" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637757707379409980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637757707379409980" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637757707379409980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_637757707379409980" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637757707379419969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_637757707379419969" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140425240586040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 22, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 22,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protalix BioTherapeutics,&#160;Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>plx-20211222x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plx-20211222.xsd" xlink:type="simple"/>
    <context id="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-12-22</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Tc_BTTMuXwL2EyPjlGhGXAyjw_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Tc_QAZNlvVmmEadpHL4eE11tw_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Narr_GZpDRhuzZEerNWgWRPCJaQ">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Narr_431cSt0_50mYBGraa2QtfA">2021-12-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Narr_BiFl7KTQ6EOGzM8AMf22Eg">Protalix BioTherapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Tc_zrqhGfjebEm6K3ytZxi6_w_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Tc_-C-Cj_S2WUSm7V2s3iKgsg_1_2">001-33357</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Tc_Exh1MAeuJkWlK6pDTLIB_Q_1_4">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Tc_r1KFQWCodku_LkyNbqIwFg_4_0">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Tc_rh5osS5bAkWfrulYV5HNxw_5_0">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Narr_2B-vNzHF2kaVAejO-RFQcQ">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Narr_ppcSCaOqPkOybELWhh1kyA">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Tc_DH5KRDoORU6U3MhkvarZ4w_6_4">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Narr_ujUSOvm8xE-mSa6NUikTRQ">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Narr_c3IMqfLuMk66O8rpKMvnaQ">696-9345</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Narr_VN0IoKP4EkqAWxBYgdmLpg">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Narr_1BbteBbaBUijuInXVd3MtQ">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Narr_6Jw7rhA2MEq0LeETLukPgQ">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Narr_ayfTsc6JwE2flfm-DPpcAw">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Tc_H2dHTd2ZnUev3gEVDJe3xA_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Tc_MtF2o-AgVEqlJqdji3nqNQ_2_1">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Tc__mS0qDKbdU-6-M-gUoiBDw_2_2">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g"
      id="Narr_txuug4Xl3U2q7UAr_j98ZA">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4$L! A0#%     @ [3:64WEW+LCN    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ [3:64YE<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " #M-I937*8=258$   +$0  &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ [3:64Y^@&_"Q @  X@P
M  T              ( !F0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #M
M-I93EXJ[',     3 @  "P              @ %U#P  7W)E;',O+G)E;'-0
M2P$"% ,4    " #M-I93'#AEZC\!   \ @  #P              @ %>$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ [3:64R0>FZ*M    ^ $  !H
M             ( !RA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ [3:64V60>9(9 0  SP,  !,              ( !KQ(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ^1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>118</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="plx-20211222x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="plx-20211222x8k.htm">plx-20211222x8k.htm</File>
    <File>plx-20211222.xsd</File>
    <File>plx-20211222_lab.xml</File>
    <File>plx-20211222_pre.xml</File>
    <File>plx-20211222xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20211222x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "plx-20211222x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20211222_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20211222_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20211222.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 118,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "plx",
   "nsuri": "http://protalix.com/20211222",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211222x8k.htm",
      "contextRef": "Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211222x8k.htm",
      "contextRef": "Duration_12_22_2021_To_12_22_2021_dpjc2DoqDUau1A5XVPKX8g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "plx_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://protalix.com/20211222",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001558370-21-016986-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-016986-xbrl.zip
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M63Z[,&6C_+2U.;:-UE;JZA=02P,$%     @ [3:64\%SH;V>!0  Z3X  !0
M  !P;'@M,C R,3$R,C)?;&%B+GAM;-6;_V_B-AC&?Y^T_^$=^V63+H2DNMM
M;4^T=S=5H]?J8-IITW0*B0%KP49.*/#?SW9B(,$.W[K(2*=>&C]^_#[F@^-
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M0-AMHW3M;D;N\2/Q)]_YJ;SW[7]02P,$%     @ [3:64PJ3=Y*=!   2BH
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M0%<)^F8IJ%+*(Y).*416%4Z0595+MC694R15Y#*:DDM+.$-2&356$_PZ[KK
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M. L[^ $$5I3%UM'=:?UBXNX>O!U5VW 2@0^U?+W^;"!^^ALK#%-D[]B>#D;
M/#)?E:8%K/M8@7O+*W"K\S8\JF*C\J5::-[4RXVM:'[\J]/!)HX'3Z=A_'#=
MP#0K5)_>_:%YQABIV&,[-OP(>W"&/PR0.\ *>& %7TQ52!<;;1:M917YX>&P
M0)=0XK$PLU\=]MRN1:%3&O^B:XP[$;E\G%Y2:3ZU\&S&+B_5K;,+E)??Y"KD
M&EU+\])K1I8W*C69S[SFQR'_V>+QFG;WRF&W :N.?; ]O]!GC9FD@&9L4O^\
M)^^M/O@@\UOW'Y9^_+M>:Q8N*G?HM%)K?BW7"U?EFV:EV(@^_ETM\ML]A[J#
MN\)>-M7LZRKU,P*HJZ:%W:!R%<+O!I4KP7K'@M$?*KJ(RM-Q?OXD(*TQ"0B\
M(*USW&:K/4HX"52B%D6GV.GB9ZY>?2C,V\8T=DHIO_.0]J&FNT3E*ZBI?[YU
M]_64+8+I[,M]_FZO8E<G;52>Y#:N^;F-Z2L=Z=N=@.]S[>T7"I_&(TQAY'(J
MQC1]CSFWLC WZCJP=&U^T/71_54L;0R_NF[?./E_4$L#!!0    ( .TVEE/=
M_@C*/!@  ');   7    <&QX+3(P,C$Q,C(R>&5X.3ED,2YH=&WM7/ESV[:V
M_E?PG"[IC/;$22REF>?83NHWSC*)V][[(T1"$JY)0@5(R<I?_[YS %#4DC2Y
M=M)ZIIU.;%,D<'#6[RS4T_]IM\^*F2P2E8I?+E]=B-0D5:Z*4B16R1)7E[J<
MB4LSG\M"O%+6ZBP3SZU.ITJ(HTZ_W^EUGARVV\^>8JF3\(PIAJ(_Z [P?V_0
M%_W^\' P?- 3QZ_$_5\O3W[BVT_?G%S^^^V9W_;MK\\OSD_$0;O;_?W!2;=[
M>GGJ/WC8Z?7%I96%TZ4VA<RZW;/7!^)@5I;S8;>[7"X[RP<=8Z?=RW?=69EG
M#[N9,4YUTC(]>/:4KN!?)=-G3W-52I',I'6J_/G@U\L7[2>XH]1EIIX][<:?
M_MZQ25?/GJ9Z(5RYRM3/![FT4UVT2S/'0>;E"$]V\?'6/=?MI4[+V;#?ZWT_
MFLLTU<6TG:E).>P/.KVC]36KI[/U1>,/-[0JDZ5>*%K]$WOG^&.F>(4'C_!W
M8T\\.(^/34Q1MB<RU]EJ^..ESI43K]52O#.Y+'YL^2OXZ935DQ]'?+?3'Q2H
MHCW\GF-3EB8?]M97^#2-OXDJ^M,LE)UD9CF<Z315Q?Y#T2:1O,B*L 58@54V
M^1.N[:Q4JNNRK0MLXTGYP']<#_NCL4RNIM9413I<SG2YLVFJW3R3JZ$N,EVH
M]C@SR57@WV$?BDP<_.'>T>AIEYYZ%G_L6\(_&^30GU^/:L[4!,NQ,UD%*AH2
MBK3V>*<G@][#T;Y=P$I9#ID-FXIT.SP9WUA): __)RTT+(S-9>:O+#U/QB9+
M/5DRT]-B2.1C[[/KF1[K4AS!>SSMCFL>=^>WJ[O#8*9-KBZTP]Z9+E=138,0
M'HR:9)#M,<T_'Q#1Y"7D.%-QE;&QJ;+MQ&29G#LUC+\TZ2"[#+I!;B'!)Y#,
MB-=I0WU,50XG^EJE03? C2=/V'Y+&_>I=8O/4:;U*90M=2*SP%=88%1AZ%?C
M\$%OZ'=QV'F(?^O?MCQ,8Z=M.XY_MY=6SH=C>/BK]A(,^%.OM6L%T55\CK\Z
MP=G&5D/&OZALH>B\)&_$@?:NT/N?%'KC1GSXF2K@G7OXMTS_8?]?S/YN:<DT
MOH(<OH;/T?E4.)M "MEUFS!0?S 87*OKHZ,4?.]W_C.?'L## (:\A%AG.CGX
M9("*P?YH+;W!D\[@,."0^==2T=MA32,$^'AV8_^\UH@N.]2H*7^3\+$##)-,
M28MX6,Y&VQAQGQ7?@DGV-OF>(/8HVS@9R[D??KDI(&C&^X-G;ZTIL>NU>*[-
MY4Q!OU4%8ITX=Z[":IP27*@2!(G2B/<E-'R&1Y5U'@Y\% =\,0>^R7E/CM^]
M.C^[:.%\5JJ,S[#C_SY[@X-G+7&J$I6/E?WA7O]1;S08M#S/NF_?X4&WU%9U
M1;LM/L9H4%(D'7'_];_?GXGC'.LFLAB^O?C73^+^Y?'[,_ZU):08:S-'.I3+
MA!^4F4A,CCQO)2;( ATG<J*<*9&JA<K,G/+"EIA;DU8)*:V014J/8(M$@Y(/
MDJ^:B; *E\>ZD&!#N2:-GBV5+EQ8!#N,5T*7_/?<:B1H=D7G.E%9=G8=;<I5
M-S;LQQUREGO<(AEP_S%A<.QR,\$).&Y*G$%[>RR)?>&X0EW/K7*.F.-6KE1Y
M"YJ?RA486 "7$Q^(S1/@2+.$/Q:9-X^)-3FSYRT>UP3MF>4G,ZTFXNQ:)16Y
M#/%F,M&)LE <:ZQX+AT2>MJ!'W4-^^*G:2==+)0K?9X/^54%7%KGSX'X;1K@
M33A]"G>Z5O^F!VG=G4,<.[%4(C/F2E"&QK*Q:I*II/1VIV$6TI5BA=/"IH7,
M2:&JE S,5'">"E?H*?Q-0L6'4U(S6G8FH1>Y3$G4L/02F]-ME(;HHH*^G9B%
M3MO]HS8''EP@-;2EU$4)M4RLP3HR(X]@"]*<L,<T,V/5$;_/--(AWA0$J!RF
M/9-X #$Q;06WX'=RI(>XW@(U<"S)#(NJ8DK79Q+J;$%75<8CT5/69"TZ@E4Y
MJ,$/#U]YU0V_A,>1SR8SL<365*;"W1N+Z"+)*L(W?-G,X8=\#:DE$J K]GB>
MZ],*3##P/8#65SB>JNDG\G-YU> N^3TP!K99E-ZB)MKFV4J,5:;A* -ERI_-
M.U#&/>!5.<,1[%):F*&A'T[D2A8@<5*!JH7,*M7VF$Q D6"CIE#!;*D&-J$L
MVY]!)!+J#V_B[I#A>B4&&B(A@K.@"1J_$C/P)V,>.>,UE226&W"P,#[W;K(C
MF1&C4])MBHQ?EP$W.W.C1*+)727[(,2[M0(>IPNJQI)K=G='KI=FJBC.^VHQ
MR:X!&3X"$^;2E@5%+0IG3HL7:R2BQ?O.O'/<83] F 3Q$.*6XG(U5^(8-H.C
MPD0@_S=)"8\4-B93^[7SON.!TPMC4M[[U%93,#:'R;O2^P!Q_\7I\4]DC/P0
MD%!FI@12(2%5.!CO?(Y?P[W/+\*];]_]J]WO#>KG2BIX\QFALC*M,C9R3<+S
M%+V08P@521VI/#N6*9P:SI)DTB+HDN^!&Z##T'H@BO*)_N.1(]" 4, 4N.A2
MR=.0^P.#R9DLY8I)@5^JQKGV"(,HJ0D%Y2W&);1GI-H!G6$]N.()W0T3&MPE
M'U)0/.&LJ;45ZO*Y00C#TK6S#B$!\*O=8)$$?%U@!8Y.[(TE@5G2O#D'PU?2
M7GD5.Z[*F;%19X^;6O'J&%I1Z]U9!0BKN$F28AWR4\=3520K<?_LU?%/'8!R
M)B4J;-3A>H%W4#F0KW /@SS3;EP)X1<K\9DC"H390+<0$UV D*!)N 2$\"U!
MUT &0E\F@'!IO5H/FB>."L,+K#FUK3I00""2/RK8KK+?1GF^@?\]B6C@CGI?
M""8CI!A\3]3ZM\!D2IR?GXMX%GU;3#QX]OSXXOCUR=G3KKYAUE1#L=)J@F92
M#!ZV<ZPR:PE@GM3DX!_P8VHJP@%CW$X8,^'4)V ];%ZE*]+'J,=@@?>]F_X8
M+D(B?R;,1QAJ M3K'0DR5J47,1'3]&%JG&J&&(8:Y,+7=H/'",R0'5=%FTDC
M8_&/ Y_1XPV/NV4W0D[H+T*3'NS2.C6][-?6P8^6B8QIQ!V 6FW2CKCD-!W+
M(<IY_P1X1=;+#W[$NC]IU0RK?1X;4*RF(I*FG(. IZZ3@OX@D,5']MZ&2.;T
ME6[X.ZL?:TXK9A+*1IEZ>/E_5:%8\)1-B%#48/:R.B&N++2I7$:!G'TUDGXN
MZ4%VS WF06V,'IA\+8M\=_[RE\N;<X0BQ]<A[_3EK?N+NY3]G$F+#-%&I^#S
M>H[FL0I4ZTYIYE3_9V27P1G<037:]>O13[0H%R_:F43&W!(.EI3,VM3H"FX\
M!:Z9%CY#5)03DZ=E-RHGJH2Q*BIXR63%JAI*F.8*_.(Z<R,*+#2Y8&#^A0*+
MG;A__MM/N#"I'*-J\G2>E_FT>S4%KO0Y@J((@00&X>,A!*2NW)YXTK#]LCDK
M(QNY#CZ3"ZDSSF!5\6&5DTCAECW&"+51@HCO+@$1+[>D'OSKWUC(7F (>X2*
M0^EC@Z4-86QP=[P2Y[_5HMAB-E5.E@IAL319B"42FC.M&1V%X&M-SE<(:H6C
M8BL^#7X:48QB:^FQ,)7#.$_;E.;=A[#&(OZ0#'Z0^7PD7E#QG510G*XS\3N$
M::.OY#+H!);$GA+INRJFL(DB9,%CF1%@%VZ&= HW6U--9TB=DYGD(B,GPT \
MCM)"XD8N_V,X\0XU)E.5]!EGX(\[A[WOQ7M5:."B]RJI+!=*"VX;D(:]-B76
M3"L/"1@^R0U00"56Z6:LE06.5] #G/IQI8O/H*D-YC_^L@T?!O\"#9Y.J6Y0
M<J7LN\.'G4>'P>9TEG':9G5!"#4CNZE""89SY,8G1>H1G>+,8<4*P@R;(WV^
MUCG6A__Z;O"XT^MM+._1YAJR,C,\J0%  637J/$U/'L>\3.(*"OF/]"1ZH@W
M"^4A: )A.!4]7AT:K=2$Q&26&U#YW6%OFQ8R:&*E^J/2%!KH5+$H $X=EVVL
MU_;Y/%:?0+\(9%-]0.;T,#MCZ(^I,GX2X)U8Q?<3:->^ #.1"Y@7R82E'@H0
ME$)X0RNFS!6G?*%6)OXQ%X2ZHZLUI>3KIE24FNA0$PTU>V<RG<;ER:N%5C'=
M$S-YKFU@51?\(#F *9<U@B70#759)!:8%4]\;M:8.Y_?P&X.!C[XW(&2OZ@)
M[_^=U2-5ZUDX&M\R=GBOQ_^-&B?<_"#,7A!-/)$1_N[M8T1S1#+,=H9+&_.>
MV_.<<SE5;3_:PQGA4&9+N7*!KX\/.T_ZWX_"T)F_UMN9$/TVDZ=_8TG_Y>,6
MWS3<7QC"NU/Q(G23[DY@_SU6;"ODV][= 3465Y,J"_4(!'SO_S?[=W5--W;.
MZ.+SB^/-ZG?(K7XM-.'$]P"!RHT:E>%8=^?IA>UZ"![V9=S15A;/>4;<O]$=
MC6W+S924;Y>;8&7#^7?$2^/[%V  D4L1K(YYW!*.;4(.^5."O>NR4P@"H46Y
MPQ^&N(O@X25.0I.G%$&FW!#)X&$*5OZZ_N.Q<#T)T IS I *KZSR>696"I(-
M#VC\JZE,@MV0BX&UO&MJ]8+VK#OS\1"TW+C2F9>E+TZZA( WHEZ"V^"/^5B^
MO)8Y<(5ZKJP+AD,=$\8)H9^EX#4(J2@$Q[)9S$HRJMOQ3.[8A&Y/1 3,35\X
M;X5><4S58C^JP] 9F1O+8LFP(--7W CV+%F9RC_<'*UH\?XKOAR",YUZ0Y84
MN)&L1H&Y*DEP$A5*DWCV#M4RWFN:%P! O$,3%QOC,>N1&I\P?62HYMN>[O:F
MTH['-%;QZ1&Q;SAN=Q.QU8> ,_COAM9N,*@6W T7X#VDWAY7VYGZVC/M58^T
M==8BH<+$NO@>#P$?05V[+VMC<\8&;._3W3AU5L_81<IW*,5-KG)S5?@:S#;=
M:V+KIC3<\!_(1G=NI9S/5UU(1A3.<E7.C&\<!DF0WVORN^:QYEB,O*MR'$#;
M#F*EGFY!_OCN^)<=;GG1AH%).D\U06)8A?I7K10M08]-,PC+4L=.9A/98OWP
M@O6WA_D XM8KN4(VW1^06K2XO('T%[RGH!7N;,PT2=_"YG8W 18>U$BH+  5
M=@V-I!&N,/_ P>KM!!RS?IJ4UEP:FZ5 TY]C6YQF!,"PYW#J.D*[YU9^T%3=
MF5'IH*;%*BK888&*NF.\V%W6A";#YGJNN,P+ .=@RBR5ID=9 $_$^O2?.B@N
MN>*QJ2J%XDJH!L:LR^+12?J*AFN"ZLV1TZBE"17#J#CCAF(.)2KT%( ,5VK9
M29&;U)<K:#\D:!_P:R Z5G":=,\JL$G\<._HX>&H_1) ."F-7[%]7'NKO2,U
M&^,S(WHG*S4 KX$4$2=R^KW6_N<70%M4]_<4P$'-M?5&$=9TM,:ZS#,*ZQW2
M*1ON<AT%FN=Z>_9R%88G:<;:J?U$6#6Q=&3L.D50CGL<?72/C$K=OH(D3E]S
M#W__RJ_/+ET]P!E/-/(SH:0LV\8=(&[L5'QJ\(JRY[W)E%^]*@D\[7ZZEL-G
MA=]]"O:-S?SV(%?(Q=LQ-V>.A++[UP):-Q_<8V&IZ]*WHR2M%,GV\M?<ZD+&
M%?KB7+$L#-T(K2]Y>A.9$%D =?DRFC-":M]8AAX(.5 [\\SQ*29]X*O2E745
MNSA3-_K:<&!(X,A!4"$H^$.>9D">2<5OKIC[N':!'U.O5N\43<F*XX1-I']T
M=.CKU30;X01YY$%OY(?K6OQ7?Q2OK@<[MC\)L[W;E^%PN4Z^?1TT_V?/^KE<
M[=P)![!];:FS;.<:):+;%WW5.EXDCH8/J*Y?K&^O'0*%\)1]WGQFO?N;"*>A
M+C+6B5DH_GF/ CA)TI/5M@@;$HZE[X_?P:L"J!!7:-&KPBS]^R-5X7^WVEVY
M<"5.HNLX)@[&(3!5I'S 3SRX0S"*9R01-:FPX@>Y?=\4&R! 36C*3M+("C=B
MZVF4!E6D?)'X+6+KR1<N$U36DH&P&DP\F9OSF<Z7Y:'X@32X2+@\PE>,VVE,
MSW"3DYYM.D==+$Q&W0J>@L9'4ZNX$4(<J=_8\#-%C<:PW*HZ,8_&*AP\6',1
M7@P V307A-VIO0'1N$:YI+E*!]& 0E7D.\]D>\Y'5M8[),H%-*%:H3_KH\XP
M"#-&IF#4)=$PW:REU:\N*,2F.BR [FJ>\K-4X)-IRME&P"PG[RZ:P[BC3^W6
M:I3M"E_(R?2,,BILXWE:)T\-C,W\#77%,I+1' !FX*TG-4!G_,H6%N\@(R9Y
M; P#A)(/0.THO!< $7L$YW=NQ3%/LE%OLM@68:;X&*(GL9,WEE@94<W82!/A
MM'J,M3G./-%9F.B,M-)#Q;HERMONXL&1F$B=L6Y33I?)500(?,8P-^D!%4^M
M!6F& =Q:T6AF0 <@L54YC7-809=9\3CY<30@0';OM;,!8X?" <%R%U$6P2@)
MIS%6(8@19B)!@*TT0Z<17 QQU2E5A)D2WY7%$3=GZ/!\:ECQXN<9O:J#RPHV
MP".(!>E66G%5;^LT(U I?0.#N%(5I!.XKPB:G].D,.[V;V-1_#+A'2T ^U*7
M56@QTJ )@OC8<-D;^NU1^V;IF7"T2<SFKO3RB@$^,W8]MP*7]T?E>[N!;!(_
M3R+6X#*$#%L?UU54#F-&3BK?+2<ZN#FI]M7 ]^EWPWOMJYJSQ3"P" 54GE'V
MBNOG.Z3.?<3R,@-]&Y- O%$HA6_I[GIQK@-[@.IX$M1+DH,BW\0WX(STL?_6
M!T*ZC;N\?51%K6OTG3+02WA'1\6U#8<4.,75ZH90J+IMJ6=M>9HE--]I5[LS
MEI T!@)XH*"V5R:$9D['((.URM>4N):O>&[ H_6-S<V8@NO>'K:/HM1S!^_F
MU'ZB%0M%3HNB1VB3;Q<8H@?%#[H3ILO[\_L[#"T!)2)7I'.&2O8Q"?FG[_Q/
MW_F?OO/?KX3%2.O-;^>G[?X1N2/6$_8/5%21/'RW#M8RI?H/Q12:L$^\&QY7
MCMZ#<:W/#?\?\YQA"#2^<L[9HN;T+HZ\),V^YN=YX +:SU?]74#Q,SU?O\"V
M;B RWDBIYJ['%8=H#J=<2MF[51P^H^3)C\RWZH%>3FC7<'P]([X=#>NW2,-P
M,#]9<75O#^+EUD%S\&BI6"X^;$6<QL\GG@:?0ONQJ5@=I)4VO7\CR(>\AF"3
MM,EL)X]9OU35JM\XXB2_T;%8^)2M<$'^]+HMASB_G3^8STFG!?6&J2:0R26)
M>Z-VV6B] M3'W#]JI'8,2=?C )F>*-]QIJ3%*0*1H_">XIS"$S.XH+<I^!5;
M^I/3 8ULED2]\F6(-+P*#2M9Z"0<@N *TL( >:+^3S:8P^]>YW,/QGT=-]A
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M+GAS9%!+ 0(4 Q0    ( .TVEE/!<Z&]G@4  .D^   4              "
M >\#  !P;'@M,C R,3$R,C)?;&%B+GAM;%!+ 0(4 Q0    ( .TVEE,*DW>2
MG00  $HJ   4              "  ;\)  !P;'@M,C R,3$R,C)?<')E+GAM
M;%!+ 0(4 Q0    ( .TVEE,@% 9NX10  %&?   3              "  8X.
M  !P;'@M,C R,3$R,C)X.&LN:'1M4$L! A0#%     @ [3:64]W^",H\&
M<EL  !<              ( !H",  '!L>"TR,#(Q,3(R,GAE>#DY9#$N:'1M
64$L%!@     %  4 2 $  !$\      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
